Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
ID05626426

An Open-Label Study to Evaluate Safety and Effectiveness of Repetitive Transorbital Alternating Current Stimulation for Optic Neuropathies

Led by Stanford University · Updated on 2025-07-08

40

Participants Needed

1

Research Sites

52 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are evaluating the safety and effectiveness of long-term electrical stimulation using a home-based device for treating open-angle glaucoma, a condition where the optic nerve deteriorates faster than usual regardless of eye pressure. This open-label study focuses on patients who are safe to participate but do not meet the exact criteria for a randomized trial. The goal is to understand how repetitive transorbital alternating current stimulation (rtACS) affects optic neuropathies. Participants will receive active electrical stimulation treatment every other day for eight weeks using a headband device that delivers current to the retina. This treatment period is part of a study designed to monitor changes over time in the visual field and other eye health markers using specialized tests and imaging. Throughout the study, participants will undergo regular assessments including visual field tests (Humphrey Visual Field Index and Mean Deviation), optical coherence tomography for retinal layers, visual acuity tests, and various imaging techniques to evaluate retinal and optic nerve health. These evaluations occur from baseline through six months. The study includes monitoring for safety and effectiveness, with participants involved in scheduled visits and follow-ups to track their progress and any changes in vision.

CONDITIONS

Brief Title

Electrical Stimulation for the Treatment of Optic Neuropathies

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Participant must be at least 18 years old.
  • Participant must be able to follow study requirements and complete the schedule of events.
  • Clinical diagnosis of glaucoma with mean deviation worse than -3 on Humphrey Visual Field 24-2 test.
  • Reliable visual field measures with fixation losses and false positives not exceeding 20%.
  • Eye pressure must be clinically stable according to investigator.
  • If two eyes qualify, the worse eye or participant's choice will be enrolled.
  • Participant must understand and sign informed consent; assistance provided if vision is impaired.
Not Eligible

You will not qualify if you...

  • Inability to comply with study procedures or follow-up visits.
  • History of ocular herpes zoster.
  • Pathological nystagmus.
  • Visually significant retinopathy such as diabetic retinopathy or retinitis pigmentosa.
  • Corneal opacification or lack of optical clarity.
  • Uveitis or other ocular inflammatory diseases.
  • Presence of any electronic implants like pacemakers.
  • Acute conjunctivitis.
  • Acute autoimmune disease.
  • Pregnancy or lactation.
  • Physical or mental conditions increasing risk or interfering with study, including dementia.
  • Unresected brain tumors.
  • Implanted intracranial magnetic metals incompatible with MRI.
  • Skin damage.
  • Children and comatose patients.
  • History of epileptic seizure within last 10 years.
  • Uncontrolled hypertension or diabetes.
  • Inability or unwillingness to travel or complete study schedule.
  • Prior participation in vision training/stimulation study within last 12 months.

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Treatment

Duration - 8 weeks

Participants receive electrical stimulation treatment every other day via a headband that delivers stimulation to the retina.

Approximately 28 treatment sessions every other day

Follow-up

Duration - Up to 6 months

Participants are monitored for safety and effectiveness with assessments continuing through 6 months after treatment.

Follow-up visits at scheduled intervals up to 6 months

Trial Site Locations

Total: 1 location

1

Byers Eye Institute

Palo Alto, California, United States, 94303

Actively Recruiting

Loading map...

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Similar Trials

ICVP - A Phase I Clinical Trial to Determine the Feasibility...

Ocular Injury

Actively Recruiting

1 location

A Prospective Study on the Efficacy of Direct Selective Lase...

Primary Open Angle Glaucoma

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here